Purifas® understands professional therapists and businesses highly regard the opinion of their patients and clients. In June 2018, we conducted market research to find out what is important to them and what they thought of the Purifas® FaceShield™ and Purifas FacePad®.
Is there a risk of Cross Infection? Our research shows there is.
In August 2019, we randomly swabbed the internal aspect of the face hole of five therapy beds from five different private clinics in Australia for analysis. The swabs showed the face holes carry viruses and bacteria.
Purifas® FaceShield™ was put to the test. Just how much bacterial filtration can it provide? We conducted two tests for Bacterial Filtration Efficiency (BFE) through two reputable, independent international laboratory. The results speak for themselves.
Purifas® conducted a clinical trial to determine the difference in bacterial transfer from the client to the therapy bed with and without the use of a FaceShield™. The results are clear – using a FaceShield™ during treatment significantly reduces the transfer of bacteria to the therapy bed.
In November 2021, Purifas sponsored a clinical trial that was developed and completed by an independent microbiologist from Macquarie University in Sydney. Find out how the effectiveness of our FaceShield compares to an antibacterial wipe